) recently announced that a decentralized marketing authorization
application (MAA) for its quadrivalent flu vaccine, Vaxigrip, has
been accepted for review in the EU.
The Vaxigrip quadrivalent formulation contains two strains of
influenza A and two strains of influenza B, thus providing it
with an edge over the currently available trivalent Vaxigrip
version. Vaxigrip trivalent contains two strains of influenza A
and one strain of influenza B.
We note that Sanofi's influenza vaccine portfolio also includes
Fluzone. Sanofi is looking to get the quadrivalent formulation of
Fluzone approved in the US. To achieve this objective, the
company submitted a Supplemental Biologics License Application
(sBLA) with the US Food and Drug Administration (FDA) last year.
A final decision from the FDA is expected in the second quarter
We note that in the US,
) FluMist Quadrivalent and
) Fluarix already approved.
We note that Sanofi possesses one of the world's leading vaccine
operations, with total sales of €3.9 billion in 2012. The
company's portfolio includes pediatric vaccines, influenza
vaccines, adult and adolescent booster vaccines, meningitis
vaccines, and travel and endemic vaccines. Sanofi also has a
strong position in both seasonal and pre-pandemic influenza
Sanofi continues to expand its vaccine business. We like what we
see in the vaccine pipeline and expect a significant ramp in
vaccine sales over the next several years. Sanofi has beefed up
its Chinese presence with a new vaccine manufacturing facility in
Sanofi carries a Zacks Rank #4 (Sell) in the short run. Right
) looks more attractive in the pharma space with a Zacks Rank #2
ALLERGAN INC (AGN): Free Stock Analysis
ASTRAZENECA PLC (AZN): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.